Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2 fusion
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR2 mutation (30)
FGFR2 N549K (7)
FGFR2 rearrangement (7)
FGFR2 P253R (3)
FGFR2 K310R (2)
FGFR2 translocation (2)
ARID1A K1238fs + FGFR2 R210Q (1)
BAP1 mutation + FGFR2 rearrangement (1)
FDFT1 rearrangement + FGFR2 rearrangement (1)
FGFR2 A391E (1)
FGFR2 B252W (1)
FGFR2 C382R (1)
FGFR2 E250G (1)
FGFR2 E565A (1)
FGFR2 E565G (1)
FGFR2 E565K (1)
FGFR2 F276C (1)
FGFR2 M540_I541insMM (1)
FGFR2 N549D (1)
FGFR2 N549H (1)
FGFR2 N549T (1)
FGFR2 N550K (1)
FGFR2 S252W (1)
FGFR2 V564F (1)
FGFR2 V564I (1)
FGFR2 V564L (1)
FGFR2 Y375C (1)
FGFR2 Y376C (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CB mutation + FGFR2 rearrangement (1)
PIK3R1 mutation + FGFR2 rearrangement (1)
TP53 mutation + FGFR2 rearrangement (1)
FGFR2 C383R (0)
FGFR2 K660N (0)
FGFR2 W290C (0)
FGFR2 wild-type (0)
FGFR2 mutation (30)
FGFR2 N549K (7)
FGFR2 rearrangement (7)
FGFR2 P253R (3)
FGFR2 K310R (2)
FGFR2 translocation (2)
ARID1A K1238fs + FGFR2 R210Q (1)
BAP1 mutation + FGFR2 rearrangement (1)
FDFT1 rearrangement + FGFR2 rearrangement (1)
FGFR2 A391E (1)
FGFR2 B252W (1)
FGFR2 C382R (1)
FGFR2 E250G (1)
FGFR2 E565A (1)
FGFR2 E565G (1)
FGFR2 E565K (1)
FGFR2 F276C (1)
FGFR2 M540_I541insMM (1)
FGFR2 N549D (1)
FGFR2 N549H (1)
FGFR2 N549T (1)
FGFR2 N550K (1)
FGFR2 S252W (1)
FGFR2 V564F (1)
FGFR2 V564I (1)
FGFR2 V564L (1)
FGFR2 Y375C (1)
FGFR2 Y376C (1)
PIK3CA mutation + FGFR2 rearrangement (1)
PIK3CB mutation + FGFR2 rearrangement (1)
PIK3R1 mutation + FGFR2 rearrangement (1)
TP53 mutation + FGFR2 rearrangement (1)
FGFR2 C383R (0)
FGFR2 K660N (0)
FGFR2 W290C (0)
FGFR2 wild-type (0)
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® CDx (110)
Associations
(24)
News
Trials
Search handles
@ArndtVogel
@BenWestphalen
@DrChoueiri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GIcancerDoc
@GlopesMd
@JavleMilind
@MadisonConces
@MarkYarchoan
@OncoThor
@PGrivasMDPhD
@StephenVLiu
@SuyogCancer
@VanitaNoronha
@VivekSubbiah
@bruixj
@jgong15
@kmody29
@pashtoonkasi
@sonpavde
Search handles
@ArndtVogel
@BenWestphalen
@DrChoueiri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GIcancerDoc
@GlopesMd
@JavleMilind
@MadisonConces
@MarkYarchoan
@OncoThor
@PGrivasMDPhD
@StephenVLiu
@SuyogCancer
@VanitaNoronha
@VivekSubbiah
@bruixj
@jgong15
@kmody29
@pashtoonkasi
@sonpavde
Filter by
Latest
10ms
FGFR inhibition in #urothelialcarcinoma #bladdercancer at #ASCO23 - 1)The THOR Phase III trial in advanced #urothelialcarcinoma (UC) with FGFR2/3 mutations/fusions: Erdafitinib extended overall survival (OS) v taxane or vinflunine chemotherapy (median 12.1 v 7.8 mo, HR 0.64,… https://t.co/AM7hNC5Db6 (@sonpavde)
10 months ago
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
|
Balversa (erdafitinib) • Javlor (vinflunine)
11ms
@MiteshBorad presents Phase I of FGFR2 inhibitor (RLY-4008) in cholangio & solid tumors. No MTD. Glad pan-FDFRi refractory FGFR2+ fusion cholangio included w ORR 21% w 70mg or greater & 11% <70mg. @ArndtVogel discussed potential for “strategic sequencing” #ASCO23 (@MadisonConces)
11 months ago
P1 data
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
lirafugratinib (RLY-4008)
12ms
🔥ESMO-MCBS monthly approval UPDATE🔥 ✅CHMP adopted positive opinion for Futibatinib 🎯💊in FGFR2-fusion+ #cholangiocarcinoma based on FOENIX-CCA2 👉ESMO-MCBS score of 3 https://t.co/6PnAvHNYyf @myESMO @EASLedu @CcaEns @OncoAlert #livertwitter https://t.co/sgw4tbxVHX (@ArndtVogel)
12 months ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Lytgobi (futibatinib)
12ms
🔥ESMO-MCBS monthly approval UPDATE🔥 ✅CHMP adopted positive opinion for Futibatinib 🎯💊in FGFR2-fusion+ #cholangiocarcinoma 👉ESMO-MCBS score of 3, based on FOENIX-CCA2 https://t.co/6PnAvHNYyf @myESMO @EASLedu @CcaEns @OncoAlert #livertwitter (@ArndtVogel)
12 months ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Lytgobi (futibatinib)
1year
🔥CHMP ISSUES POSITIVE OPINION FOR FUTIBATINIB FOR THE TREATMENT OF ADULTS WITH CHOLANGIOCARCINOMA 👉Good news and more options for patients with FGFR2 fusions @myESMO @OncoAlert @EASLedu @CcaEns (@ArndtVogel)
1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Lytgobi (futibatinib)
1year
🔥Specific recognition of an FGFR2 fusion by TILs from a patient with metastatic #cholangiocarcinoma @jitcancer https://t.co/1YJlIOrDWS 👉FGFR2 fusions can be immunogenic 🤔Proof of concept to explore T cell-based therapy targeting FGFR2 fusions in BTC @myESMO @EASLedu… https://t.co/9ahgt9mooB (@ArndtVogel)
1 year ago
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
1year
What drug is this patient on...? A patient with intrahepatic cholangiocarcinoma with FGFR2 fusion. Responding nicely to pemigatinib, an FDA-approved FGFR inhibitor. Tumor calcifications are sometimes seen and here is an example of that. Remember, sequence ALL biliary cancers!!! (@OncoThor)
1 year ago
Clinical • FDA event
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Pemazyre (pemigatinib)
1year
Great to see this collaborative study between @UPMCHillmanCC @JHUPath @MayoClinicPath @CLEClinicLabs. Tweetorial coming out soon, but if you are interested in Actionable Fusion Genes (FGFR2, ALK, BRAF, NRG1, RET and others) in #PancreaticCancer look to ITPNs of the #Pancreas. (@PancPathologist)
1 year ago
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • FGFR2 (Fibroblast growth factor receptor 2) • NRG1 (Neuregulin 1)
|
FGFR2 fusion • ALK fusion • NRG1 fusion
over1year
We have similarly seen a predilection for FGFR2 fusions and female patients among iCCAs. One wonders if this can be associated with specific precursor neoplasms? #Cholangiocarcinoma (@PancPathologist)
over 1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over1year
🔥The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma @HEP_Journal https://t.co/TC5aUZdkWK 🔥Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma @trendscancer https://t.co/JCPSnToFCc (@ArndtVogel)
over 1 year ago
Combination therapy
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
over1year
👉In depth analysis of co-alterations in 713 pts with FGFR2 fusions 🔥Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma @JHepatology https://t.co/f0d7M2pqQD 👉We need data on the impact of co-alterations on the efficacy of 🎯💊 (@ArndtVogel)
over 1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over1year
11/19 #TumorBoardTuesday 👨🏽🏫Mini tweetorial 6👨🏻🏫 💉Erdafitinib 👍🏽@US_FDA accelerated approval erdafitinib in platinum-refractory met #UrothelialCarcinoma with FGFR2/3 mut or fusion 19 (see figure👇🏽) ✨phase 3 THOR trial ongoing 📚https://t.co/CCNB5pXn4N 🔗https://t.co/PbJFN0gqkF (@rafee_talukder)
over 1 year ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Balversa (erdafitinib)
over1year
Watch: @SKamath_MD discusses the prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma. #oncology https://t.co/aJrfr3CdBK (@OncLive)
over 1 year ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over1year
🔥Precision oncology for biliary tract tumors: it’s written in blood! @Annals_Oncology https://t.co/bx2U8tcO06 👉High concordance between tissue & liquid biopsy ❗️But be aware: FGFR2 fusions are challenging @myESMO @OncoAlert @EASLedu #livertwitter https://t.co/ESmAGSlgDV (@ArndtVogel)
over 1 year ago
Liquid biopsy
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over1year
🔥FGFR mRNA in cholangiocarcinoma & its correlation with FGFR2 fusion status and immune signatures🔥 @CCR_AACR https://t.co/wbOxQY5MZw 👉FGFR2 fusion = low PDL-1 & high CSF1R expression 👉Oncodriver impact iTME 👉Supporting our ongoing ADVANCE phs-2 in #CCA @myESMO @EASLedu (@ArndtVogel)
over 1 year ago
IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • CSF1R (Colony stimulating factor 1 receptor)
|
PD-L1 expression • FGFR2 fusion • PD-L1-L
over1year
A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement. #lcsm @MSKCancerCenter @GABOUALFA https://t.co/3zw9NXWgap (@TargetedOnc)
over 1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Pemazyre (pemigatinib)
over1year
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a novel cfDNA algorithm for treatment w RLY-4008, a highly selective irreversible FGFR2 inhibitor #ENAsymp22 @AliSchram @OncoAlert @Relay_Tx (@VivekSubbiah)
over 1 year ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
lirafugratinib (RLY-4008)
over1year
🎯On behalf of all co-investigators presenting👉Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a novel cfDNA algorithm for treatment w RLY-4008, a highly selective irreversible FGFR2 inhibitor #ENAsymp22 @AliSchram @OncoAlert @Relay_Tx (@VivekSubbiah)
over 1 year ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
lirafugratinib (RLY-4008)
over1year
In the FIGHT-101, study of pemigatinib we had a patient with FGFR2 fusion + pancreatic cancer who achieved a partial response. Yes, @Aiims1742 we need to look 👀 for these fusions #PrecisionOncology https://t.co/Tj8hYCcGu8 https://t.co/8Xn6qnZLL0 (@VivekSubbiah)
over 1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Pemazyre (pemigatinib)
over1year
Pemigatinib showed a strong survival benefit in patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement, according to final results of a study presented at #ILCA22. @GABOUALFA @MSKCancerCenter https://t.co/jA8ESAluK8 (@TargetedOnc)
over 1 year ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Pemazyre (pemigatinib)
over1year
🔥Comprehensive characterization of KRAS WT #pancreaticcancer🔥 @NatureComms https://t.co/Z8m292E6Bg 👉high freq. of fusions (6-67%)>BRAF, NRG1, NTRK, FGFR2 👉R5A2, PROX1 & chr1q amplification > druggable 🎯? 👉transcriptome similar to #CCA 🧐KRAS testing in #PDAC key @myESMO (@ArndtVogel)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS wild-type • FGFR2 fusion • RAS wild-type • NRG1 fusion
over1year
Adding another recent #KRAS WT #PDAC case w/#FGFR2 fusion w/exceptional response to #erdafitinib to the collection from our @CSCancerCare team @DrHendifar @DrArsenOsipov #pancsm @PrecOncNews https://t.co/9o8kNJFLmS @JNCCN @TumorBoardTues (@jgong15)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2)
|
KRAS wild-type • FGFR2 fusion • RAS wild-type
|
Balversa (erdafitinib)
over1year
🔥FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? 🔥 https://t.co/Pjgui96OTQ ✅4 intersting cases responding to FGFRi 👉all KRAS WT with comparable long survival 🧐non-typical fusion partners 🎯Early NGS in KRAS WT #PDAC❗️ @myESMO @OncoAlert (@ArndtVogel)
over 1 year ago
Clinical • Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2)
|
KRAS wild-type • FGFR2 fusion • RAS wild-type
over1year
🔥just published: Genomic architecture of FGFR2 fusions in #cholangiocarcinoma and its implication for molecular testing🔥 @BrJCancer https://t.co/aqDgYP7Ta9 👉Our detailed overview on technical & biological aspects of FGFR2 fusion detection @myESMO @OncoAlert @enscca @EASLedu (@ArndtVogel)
over 1 year ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over1year
Another kind of FGFR2; not the fusions🧬 but amplifications⏫ relevant to Upper GI cancers. The drug here is BEMA (Bemartizumab). Monoclonal antibody. In the HER2➖ ~30%. The test actually is IHC🔬 or #ctDNA in the actual trial. https://t.co/lqDMqrrrWL (@pashtoonkasi)
over 1 year ago
Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over1year
JUST IN: @US_FDA approves to futibatinib (20 mg/d) in metastatic intrahepatic cholangiocarcinoma w/FGFR2 gene fusions/rearrangements. ORR was 42% in TAS-120-101 trial with top AEs: nail toxicity, MSK pain/GI. @ASCO @OncoAlert (@DrChoueiri)
over 1 year ago
FDA event
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Lytgobi (futibatinib)
over1year
🔥comprehensive study on ctDNA in #cholangiocarcinoma 🔥 @Annals_Oncology https://t.co/W2XI9ZDq4C ✅1,671 pts. Guardant360 🎯GA in 44% 💪Concordance⬆️ btw cfDNA & tissue for IDH1 and BRA, but ⬇️ for FGFR2 fusion 18%🤨 👉Excellent, but know limitations 👏@lipika_goyal @myESMO ()
over 1 year ago
Clinical • Circulating tumor DNA
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
FGFR2 fusion
|
Guardant360® CDx
over1year
There are reports of FGFR2 fusions in hepatocellular carcinoma and non small cell lung cancer. It is not BCR-ABL and CML . (@SuyogCancer)
over 1 year ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
almost2years
For patients with solid tumors, there is a compassionate access program for erdafitinib, but i think that's for FGFR2 and FGFR3 fusions only. Tagging @drakhilkapoor1 for any additional information. (@VanitaNoronha)
almost 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR2 fusion • FGFR3 fusion
|
Balversa (erdafitinib)
almost2years
🔥Detection of FGFR2 fusions is challenging❗️ https://t.co/aqDgYOQiiB ✅🔥🎯in #Cholangiocarcinoma #PancreaticCancer... 👇we provide detailed analysis on genomic architecture of FGFR2 fusions & implication for molecular testing 👉know your NGS Panel @myESMO @enscca @OncoAlert (@ArndtVogel)
almost 2 years ago
Next-generation sequencing
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
almost2years
It’s absolutely amazing to see how many active compounds targeting FGFR2 fusions are available for our patients with #BiliaryTractCancer - great slide by @ArndtVogel ⭐️ #@OncoAlert 🚨#PrecisionMedicine @pashtoonkasi @GABOUALFA @VivekSubbiah (@BenWestphalen)
almost 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
almost2years
Research on FGFR2 fusion in #cholangiocarcinoma is an incredible experience. Doing research with @SaborowskiAnna doi: 10.1002/hep.31799 Discuss data with #OresteSegatto https://t.co/sZckA4AktA Being part of FIGHT-202 —> getting approval by EMA/ FDA 🙏 @myESMO @CcaEns (@ArndtVogel)
almost 2 years ago
FDA event
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
almost2years
🔥FGFR2 alterations in #cholangiocarcinoma 👉fusion: FGFR2 intron 17/exon 18 breakpoint; partner is known or novel/in-frame with FGFR2 👉rearrangement: gene is out-of-frame with ex. 17 👉truncation: loss of neg. regulatory element 👉In-Frame Deletion.. ✅all druggable @myESMO (@ArndtVogel)
almost 2 years ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
almost2years
FOENIX-CCA2 Analysis Confirms Safety and Efficacy of Futibatinib for Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements https://t.co/XIJp391uWH @asco #ASCO22 (@GlopesMd)
almost 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Lytgobi (futibatinib)
almost2years
🚨Happening now: Abstract 4009: Updated results of the #FOENIXCCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma #iCCA harboring #FGFR2 fusions/rearrangements. #HPBCSM 📍Hall D1 @rachnatshroff #ASCO22 @ASCO (@Charbel_matar1)
almost 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Lytgobi (futibatinib)
almost2years
Interesting post-hoc analysis of FIGHT-202. Relative short PFS on CTx for patients with FGFR2 fusion —> sensitivity of tumors with draggable GA to CTx should be explored. https://t.co/UKiv1x1NZf #cholangiocarcinoma #precisiononcology #livercancer @myESMO (@ArndtVogel)
almost 2 years ago
Clinical • Retrospective data
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
almost2years
Interesting post-hoc analysis of FIGHT-202. Relative short PFS on CTx for patients with FGFR2 fusion —> sensitivity to CTx of tumors with druggable GA should be explored. https://t.co/UKiv1x1NZf… #cholangiocarcinoma #precisiononcology #livercancer @myESMO (@ArndtVogel)
almost 2 years ago
Clinical • Retrospective data
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
2years
MUST SEE TV @rachnatshroff on precision oncology in #cholangiocarcinoma. *Importance of biomarker testing *#FGFR inhibitor infigratinib in #FGFR2-fusion-positive CC. Presented by @melinda_bachini for @curecc #cholangiotwitter #livertwitter #onctwitter https://t.co/r6OGBu5riE (@intraccsurvivor)
2 years ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Truseltiq (infigratinib)
over2years
Erdafitinib for Advanced #urothelialcarcinoma and tumor FGFR2/3 mutations/fusions- updated results-101 treated-ORR 40%, median PFS 5.5 months (mo), DOR 6 mo (31% 1-year DOR), time to response 1.4 mo, OS 11.3 mo @y_loriot @AndreaNecchi-https://t.co/6ocRJgnLp0 @practiceupdate (@sonpavde)
over 2 years ago
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
|
Balversa (erdafitinib)
over2years
In @Cancer_Cell Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic #cholangiocarcinoma https://t.co/mDz3LbrtxM Not unexpectedly, FGFR2 fusions generate neoantigens that can be potentially targeted. Cc: @JavleMilind @rachnatshroff @curecc (@Aiims1742)
over 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
over2years
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study 2/4 @JavleMilind @GABOUALFA https://t.co/mR8QgQQRXq (@VivekSubbiah)
over 2 years ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
|
Truseltiq (infigratinib)
over2years
Promising role of ctDNA in advanced UC for patient selection based on FGFR2/3 mut/fusion (also separate promising data in the adjuvant setting) @tompowles1 @Uromigos Enjoy the read on our teamwork with @sonpavde et al. @OncoAlert @BladderCancerUS @FaltasLab @scientistatlrge (@PGrivasMDPhD)
over 2 years ago
Clinical • Circulating tumor DNA
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login